Crisdesalazine

Synonyms: AAD-2004
Crisdesalazine (AAD-2004) 是一种微粒体前列腺素 E2 合酶-1 (mPGES-1) 抑制剂,也是一种有效的自由基清除剂,能够直接中和包括过氧化氢在内的活性氧 (ROS),发挥抗细胞凋亡 (apoptosis) 及轴突损伤的神经保护作用,同时可抑制 PGE2 生成、介导炎症反应,并促进巨噬细胞从促炎 M1 表型向抗炎 M2 表型转化,因此可用于多发性硬化症和脊髓损伤中的神经保护研究。
产品编号: MS-D46197 纯度: 98.92% CAS No.: 927685-43-6 分子式: C16H14F3NO3 分子量: 325.28
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

Crisdesalazine (AAD-2004) 是一种微粒体前列腺素 E2 合酶-1 (mPGES-1) 抑制剂,也是一种有效的自由基清除剂,能够直接中和包括过氧化氢在内的活性氧 (ROS),发挥抗细胞凋亡 (apoptosis) 及轴突损伤的神经保护作用,同时可抑制 PGE2 生成、介导炎症反应,并促进巨噬细胞从促炎 M1 表型向抗炎 M2 表型转化,因此可用于多发性硬化症和脊髓损伤中的神经保护研究。

生物实验数据

生物活性 Crisdesalazine (AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and a potent free radical scavenger that directly neutralizes reactive oxygen species (ROS), including hydrogen peroxide, thereby exerting neuroprotective effects against apoptosis and axonal damage; it also inhibits PGE2 production, mediates inflammatory responses, and promotes the conversion of macrophages from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, making it useful for neuroprotection research in multiple sclerosis and spinal cord injury.
体外研究
(In Vitro)

Crisdesalazine (0.2-50 μM; 24 h) 对浓度高达 50 μM 的小鼠 RAW 264.7 巨噬细胞和浓度高达 10 μM 的人 SH-SY5Y 神经母细胞瘤细胞无细胞毒性,仅在 SH-SY5Y 细胞中使用 50 μM 浓度时才会出现细胞活力下降。
Crisdesalazine (0.2-5 μM; 24 h) 可通过下调促炎标志物与细胞因子的表达、上调抗炎标志物的表达,促进经 LPS (MS-X54539) 刺激的小鼠 RAW 264.7 巨噬细胞从促炎 M1 表型向抗炎 M2 表型转化。
Crisdesalazine (0.2-5 μM; 24 h) 可通过抑制促炎细胞因子表达并减少坏死细胞数量,降低与 LPS 刺激的小鼠 RAW 264.7 巨噬细胞共培养的人 SH-SY5Y 细胞中的神经炎症及神经元坏死。
Crisdesalazine (1 mM) 可降低原代小鼠脊髓星形胶质细胞中的 H2O2 水平,减弱星形胶质细胞反应性,并在与经 OGD/R 处理的星形胶质细胞共培养的原代小鼠皮质神经元中发挥抗细胞凋亡及轴突损伤的神经保护作用。

Cell Viability Assay

Cell Line: human neuroblastoma SH-SY5Y cells, murine macrophage RAW 264.7 cells
Concentration: 0.2, 1, 5, 10, 50 μM
Incubation Time: 24 h
Result: Significantly reduced SH-SY5Y cell viability only at the 50 μM concentration.
Did not affect RAW 264.7 cell viability at any tested concentration.

Real Time qPCR

Cell Line: LPS-stimulated murine RAW 264.7 macrophages
Concentration: 0.2, 1, 5 μM; 10 μM (excluded from subsequent experiments)
Incubation Time: 24 h post-LPS stimulation
Result: Significantly reduced mRNA expression of M1 pro-inflammatory marker iNOS and pro-inflammatory cytokines IL-1β and IL-6 compared to LPS-stimulated untreated cells at 0.2, 1, and 5 μM.
Showed no significant effect on IL-6 expression at 10 μM.
Significantly increased CD206 (M2 anti-inflammatory marker) expression in treated groups compared to LPS-stimulated untreated groups via immunofluorescence staining.

Real Time qPCR

Cell Line: co-culture system of LPS-stimulated murine RAW 264.7 macrophages and human neuroblastoma SH-SY5Y cells
Concentration: 0.2, 1, 5 μM
Incubation Time: 24 h during co-culture
Result: Significantly reduced mRNA expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in SH-SY5Y cells co-cultured with LPS-stimulated RAW 264.7 cells, with marked reductions seen at 0.2 and 5 μM.
Significantly reduced neuronal necrosis in all treated groups compared to untreated co-culture groups, with the greatest reduction observed at 0.2 μM.
体内研究
(In Vivo)

Crisdesalazine (3.3 mg/kg;腹腔注射;每日 1 次;连续 7 天) 可显著缓解临床症状,减少炎性细胞浸润与脱髓鞘病变,将小胶质细胞/巨噬细胞的极化方向向抗炎性 M2 表型偏移,并在多发性硬化的小鼠 EAE 模型中扩增调节性 T 细胞 (Treg) 群体。
Crisdesalazine (3.3 mg/kg;腹腔注射;每日 1 次;连续 15 天) 可降低脊髓损伤小鼠模型的脊髓 H2O2 水平,抑制胶质瘢痕形成与星形胶质细胞增殖,促进神经元和轴突再生,并改善其运动功能。

Animal Model: C57BL/6 (6-week-old female; EAE induced by MOG35-55 immunization with complete Freund’s adjuvant plus pertussis toxin)
Dosage: 3.3 mg/kg
Administration: i.p.; once daily; 7 days
Result: Significantly reduced EAE clinical symptom severity from day 11 to day 23 post-induction.
Decreased mononuclear cell infiltration and demyelination in the spinal cord.
Increased spinal cord expression of M2 anti-inflammatory marker CD206 and regulatory T cell marker Foxp3.
Decreased spinal cord expression of M1 pro-inflammatory marker iNOS and pro-inflammatory cytokines TNF-α, IFN-γ, IL-1β, and IL-6.
Increased percentage of CD4+CD25+Foxp3+ Treg cells in splenocytes.
Increased CD206 expression in splenocytes.
Decreased iNOS, TNF-α, and IFN-γ expression in splenocytes.
Reduced IL-6 secretion in splenocytes to levels similar to naïve mice.
Caused no drug-related adverse effects.
Animal Model: C57BL/6J (6-8 weeks old, 19-20 g, SPF grade, spinal cord injury induced via weight-drop contusion at T10 level)
Dosage: 3.3 mg/kg
Administration: i.p.; daily; 14 days
Result: Significantly reduced spinal cord H2O2 concentration compared to vehicle-treated SCI mice.
Significantly improved BMS scores and hindlimb stride length at 21 days post-injury compared to vehicle-treated SCI mice.
Mitigated SCI-induced reduction in motor neuron number and preserved spinal cord tissue structure, with smaller lesion cavities compared to vehicle-treated SCI mice.
Significantly downregulated mean fluorescence intensity of GFAP and vimentin (markers of glial scar formation) compared to vehicle-treated SCI mice.
Significantly downregulated vimentin protein expression measured via western blot compared to vehicle-treated SCI mice.
Significantly reduced mean fluorescence intensity of Ki67+/GFAP+ and PH3+/GFAP+ (markers of astrocyte proliferation) compared to vehicle-treated SCI mice.
Significantly increased mean fluorescence intensity of Neun+ and MAP2+ (markers of neuronal regeneration) compared to vehicle-treated SCI mice.
Significantly increased mean fluorescence intensity of GAP43+ and NF+ (markers of axonal regeneration) compared to vehicle-treated SCI mice.
性状 固体
颜色 White to off-white

化学信息

分子量 325.28
分子式 C16H14F3NO3
CAS No. 927685-43-6
别名 AAD-2004

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (153.71 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.0743 mL15.3714 mL30.7427 mL76.8569 mL
5 mM0.6149 mL3.0743 mL6.1485 mL15.3714 mL
10 mM0.3074 mL1.5371 mL3.0743 mL7.6857 mL
15 mM0.2050 mL1.0248 mL2.0495 mL5.1238 mL
20 mM0.1537 mL0.7686 mL1.5371 mL3.8428 mL
25 mM0.1230 mL0.6149 mL1.2297 mL3.0743 mL
30 mM0.1025 mL0.5124 mL1.0248 mL2.5619 mL
40 mM0.0769 mL0.3843 mL0.7686 mL1.9214 mL
50 mM0.0615 mL0.3074 mL0.6149 mL1.5371 mL
60 mM0.0512 mL0.2562 mL0.5124 mL1.2809 mL
80 mM0.0384 mL0.1921 mL0.3843 mL0.9607 mL
100 mM0.0307 mL0.1537 mL0.3074 mL0.7686 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础